PRESS RELEASE
News
-
-
PRESS RELEASE
Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old based on positive phase 3 study results. Dupixent would be the first medicine indicated for EoE in this age group -
-
-
PRESS RELEASE
Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
Study shows tolebrutinib delays disability progression in non-relapsing secondary progressive MS by 31%; global regulatory submissions in H2 2024. ECTRIMS 2024 data presented -
PRESS RELEASE
CP : Le tolebrutinib a permis d’allonger de 31 % le délai avant progression confirmée du handicap dans le cadre d’une étude de phase III menée chez des personnes présentant une sclérose en plaques secondairement progressive non active
Le tolebrutinib allonge de 31 % le délai avant progression du handicap dans une étude de phase III sur la sclérose en plaques. Les résultats ont été présentés au Congrès de l’ECTRIMS -
-
-
-
